A case report describes an objective tumor response to the KRAS G12C inhibitor sotorasib combined with EGFR blockade in a patient with advanced NRAS G12C-mutated, mismatch repair-deficient rectal adenocarcinoma refractory to immunotherapy. (Cureus)
Sotorasib Plus Panitumumab Produces Response in Rare NRAS G12C-Mutated MSI-H Rectal Cancer
The CRC Digest